HOSPITAL UNIVERSITARIO RUBER
Departamento
Hospital Clinico Universitario de Valencia
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Hospital Clinico Universitario de Valencia (37)
2024
-
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
The Lancet, Vol. 403, Núm. 10437, pp. 1649-1659
-
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab
Breast Cancer Research and Treatment, Vol. 205, Núm. 3, pp. 589-598
-
Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study
Breast, Vol. 77
-
Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, Vol. 65, Núm. 5, pp. 708-713
-
Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial
eClinicalMedicine, Vol. 71
2023
-
Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 1, pp. 67-80
-
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial
Neuro-Oncology, Vol. 25, Núm. 1, pp. 157-166
2022
-
Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A
Nature Communications, Vol. 13, Núm. 1
2021
-
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
Breast Cancer Research, Vol. 23, Núm. 1
-
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial
The Lancet Oncology, Vol. 22, Núm. 6, pp. 858-871
-
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
npj Precision Oncology, Vol. 5, Núm. 1
-
Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial
npj Breast Cancer, Vol. 7, Núm. 1
-
Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial
European Journal of Cancer, Vol. 148, pp. 382-394
2020
-
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
The Lancet Oncology, Vol. 21, Núm. 11, pp. 1455-1464
-
A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 420-428
-
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
Journal of the National Cancer Institute, Vol. 112, Núm. 1, pp. 46-54
-
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial
Breast Cancer Research, Vol. 22, Núm. 1
-
Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial
Clinical Cancer Research, Vol. 26, Núm. 22, pp. 5820-5829
-
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
Nature Communications, Vol. 11, Núm. 1
2019
-
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
Frontiers in Oncology, Vol. 9, Núm. APR